Month: January 2025

How Regulatory Bodies Are Driving the Shift to Animal-Origin-Free Solutions in Cell Therapy and Vaccine Development

By

Reading time: 6 minutes Share this article:   Global regulatory agencies—including the FDA (U.S. Food and Drug Administration), EMA (European Medicines Agency), WHO (World Health Organization), and PMDA (Pharmaceuticals and Medical Devices Agency of Japan)—are driving the shift to animal-origin-free (AOF) solutions in cell therapy and vaccine manufacturing. Their goal: to enhance product safety, standardize …

Enhanced Cryopreservation of T Cells Using Optibumin®, Recombinant Human Serum Albumin (rHSA)

By

Key Points Optibumin® Improves T Cell Recovery and Proliferation Post-Thaw Optibumin significantly enhances T cell viability and proliferation post-thaw compared to human blood-derived clinical HSA. Reduction of DMSO Concentrations in CryoStor® Formulations The inclusion of Optibumin solution physically displaces an equal volume of CryoStor to enable a reduction in final DMSO concentrations, improving the safety …

Advancing Vaccine Excellence

By

InVitria is transforming vaccine production with safer, scalable, and sustainable solutions. This infographic showcases how our recombinant, animal-free technologies address key challenges in traditional vaccine manufacturing, such as contamination risks, inconsistent supply, and cold chain logistics. Key highlights include: Safer Solutions: Eliminate risks from animal- and human-derived components, ensuring vaccine quality and patient safety. Scalable …